LaunchBio - The Path To Pre-Clinical
Last week's LaunchBio panel discussion on the Path to Pre-Clinical showed the journey from multiple perspectives - entrepreneur, VC, and consultancy. Moderated by BioLab's VP of Business Operations and Strategy, Danielle Bogdanowicz, the panel consisted of:
Perhaps one of the more interesting takeaways from the meeting was the acknowledgement that Project Management early on in the discovery phase of the project can have significant benefits in terms of savings in time and effort (up to 6 months), and in terms of de-risking a project.
Having a clear roadmap not only through the IND-enabling studies but through clinical trials, regulatory and commercial hurdles, can play a role in reducing timelines. Moreover, the use of a research TPP early-on in the discovery phase can help clarify the discovery goals and improve communication and trust with large pharma collaborators. This theme was echoed during a recent series of informational interviews conducted with a number of PMs in both biotech and pharmaceutical companies.
Kymanox's Hyper-Virtual model for drug development showed how companies with a small number of decision-makers (<10), could manage collaborations with a small number (<10) of CROs effectively.
It was especially interesting hearing about this approach given that it validates some of the lessons learned from our own projects. Namely that:
领英推荐
All of these lessons learned dovetailed with our own experience while creating Pipeline's PharmExchange service used to manage CRO collaborations.
I'm looking forward to seeing more in this latest series of events from LaunchBio Inc.